Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2022, Review
2022

Cancer-associated thromboses: risks of adverse clinical outcomes in real clinical practice: 616-06

Review
Published 2022-07-02
Andrey E. Orlov
Samara State Medical University, Health Ministry of Russian Federation; 89 Chapaevskaya Str., Samara 443099, Russia; Samara Regional Clinical Oncology Center; 50 Solnechnaya Str., Samara 443029, Russia
ФГБОУ ВО «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Россия, 443099 Самара, ул. Чапаевская, 89; ГБУЗ «Самарский областной клинический онкологический диспансер»; Россия, 443029 Самара, ул. Солнечная, 50
https://orcid.org/0000-0003-4816-5333 (unauthenticated)
Oleg I. Kaganov
https://orcid.org/0000-0002-4569-1031 (unauthenticated)
Gyuzel N. Iskhakova
Samara Regional Clinical Oncology Center; 50 Solnechnaya Str., Samara 443029, Russia
ГБУЗ «Самарский областной клинический онкологический диспансер»; Россия, 443029 Самара, ул. Солнечная, 50
https://orcid.org/0000-0002-2225-9051 (unauthenticated)
Iuliia G. Loginova
Samara State Medical University, Health Ministry of Russian Federation; 89 Chapaevskaya Str., Samara 443099, Russia;
ФГБОУ ВО «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Россия, 443099 Самара, ул. Чапаевская, 89;
https://orcid.org/0000-0001-5020-7374 (unauthenticated)
Irina A. Zolotovskaya
Samara State Medical University, Health Ministry of Russian Federation; 89 Chapaevskaya Str., Samara 443099, Russia;
ФГБОУ ВО «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Россия, 443099 Самара, ул. Чапаевская, 89;
https://orcid.org/0000-0002-0555-4016 (unauthenticated)
Igor L. Davydkin
https://orcid.org/0000-0003-0645-7645 (unauthenticated)

Keywords

venous thromboembolic complications
prophylaxis
heparins
oral anticoagulants
cancer-associated thrombosis
  Full Text

Abstract

Summary. The article discusses current strategies for secondary prophylaxis of cancer-associated thrombosis. Research materials and own clinical experience are presented. The possibility of oral anticoagulant use for long-term anticoagulant therapy has been evaluated.

  1. Clinical guidelines for the prevention and treatment of thromboembolic complications in cancer patients. Moscow: Minister- stvo zdravoohraneniya Rossijskoj Federacii, 2021. 31 рр. (In Russ.). Available at: Режим доступа: https://www.oncology.ru/special- ist/treatment/symptomatic/thromboembolic_disorders/recom- mendations.pdf.

  2. Noble S., Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):S2–9. DOI: 10.1038/sj.bjc.6605599.

  3. Eichinger S. Cancer-associated thrombosis: Risk factors and outcomes. Thromb Res. 2016;140 Suppl 1:S12–7. DOI: 10.1016/S0049– 3848(16)30092–5.

  4. Timp J.F., Braekkan S.K., Versteeg H.H., Cannegieter S.C. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–23. DOI: 10.1182/blood-2013–04–460121.

  5. Ay C., Dunkler D., Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–82. DOI: 10.1182/blood-2010–02–270116.

  6. Hisada Y., Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis Blood. 2017;130(13):1499–506. DOI: 10.1182/blood-2017–03–743211.

  7. Hisada Y., Mackman N. Mouse models of cancer-associated thrombosis. Thromb Res. 2018;164 Suppl 1(Suppl 1):S48–S53. DOI: 10.1016/j.thromres.2017.12.018.

  8. Prevention and treatment of venous thromboembolic complications in malignant neoplasms. Moscow: Ministerstvo zdra- voohraneniya Rossijskoj Federacii, 2018. 46 рр. (In Russ.). Available at: https://phlebolog.narod.ru/books/vteoonco.pdf.

  9. Kuderer N.M., Lyman G.H. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res. 2014;133 Suppl 2(02):S122–7. DOI: 10.1016/S0049– 3848(14)50021–7.

  10. Blom J.U., Doggen C.J.M., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. DOI: 10.1001/jama.293.6.715.

  11. Fedotkina Yu.A. Prevention of venous thromboembolic events in patients with cancer. Aterotromboz. 2019;(1):8–24. (In Russ.). DOI: 10.21518/2307–1109–2019–1–8–24.

  12. Ptushkin V.V. Prevention of thromboembolic complications in oncology. Tromboz, gemostaz i reologiya. 2013;(1):29–37. (In Russ.).

  13. Russian clinical guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya. 2010;4(2–1):2–37. (In Russ.).

  14. Markel A., Weich Y., Gaitini D. Doppler ultrasound in the diagnosis of venous thrombosis. Angiology. 1995;46(1):65–73. DOI: 10.1177/000331979504600109.

  15. van Es N., Bleker S.M., Di Nisio M. Cancer-associated unsuspected pulmonary embolism. Thromb Res. 2014;133 Suppl 2:S172–8. DOI: 10.1016/S0049–3848(14)50028-X.

  16. Easaw J.C., Shea-Budgell M.A., Wu C.M.J. et al. Canadian consensus recommendations on the management of venous thrombo- embolism in patients with cancer. Part 1: prophylaxis. Curr Oncol.2015;22(2):133–43. DOI: 10.3747/co.22.2586.

  17. Farge D., Bounameaux H., Brenner B. et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452-e466. DOI: 10.1016/S1470–2045(16)30369–2.

  18. Khorana A.A., Carrier M., Garcia D.A., Lee A.Y.Y. Guidance for the prevention and treatment of cancer-associated venous thrombo- embolism. J Thromb Thrombolysis. 2016;41(1):81–91. DOI: 10.1007/ s11239–015–1313–4.

  19. Streiff M.B., Holmstrom B., Angelini D. Cancer-associated venous thromboembolic disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181– 201. DOI: 10.6004/jnccn.2021.0047.

  1. Watson H.G., Keeling D.M., Laffan M. et al., British Committee for Standards in Haematology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640–8. DOI: 10.1111/bjh.13556.

  2. Pabinger I., Thaler J., Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013;122(12):2011–8. DOI: 10.1182/blood-2013–04–460147.

  3. Alexander M, Burbury K. A systematic review of biomarkers for the prediction of thromboembolism in lung cancer — results, practical issues and proposed strategies for future risk prediction models. Thromb Res. 2016;148:63–9. DOI: 10.1016/j. thromres.2016.10.020.

  4. Blood diseases in outpatient practice. Ed. I.L. Davydkin. Moscow: GEOTAR-Media, 2020. 272 pp. (In Russ.).

  5. Iskhakova G.N., Konovalova T.V. Features of VTEC prevention in oncological patients based on the results of the “safe territory” project. Novye tekhnologii v onkologii. 2015;(1):68–9. (In Russ.).

  6. Somonova O.V., Antukh E.A., Dolgushin B.I. et al. Practical recommendations for the prevention and treatment of thromboembolic complications in cancer patients. Malignant tumors. Prakticheskierekomendacii RUSSCO. 2020;10(3s2):131–40. (In Russ.). DOI: 10.18027/2224–5057–2020–10–3s2–47. Available at: https://phlebology-sro.ru/upload/iblock/a9e/prakticheskie-rekomendatsii- po-vteo-u-onkologicheskikh-bolnykh-2020.pdf.

  7. Somonova O. V., Antukh E. A., Vardanyan A. V. et al. Practical recommendations for the prevention and treatment of throm- boembolic complications in cancer patients. Malignant tumors. Prakticheskie rekomendacii RUSSCO. 2021;11(3s2):145–55. (In Russ.). DOI: 10.18027/2224–5057–2021–11–3s2–47. Available at: https:// rosoncoweb.ru/standarts/RUSSCO/2021/2021–47.pdf.

  8. Андрияшкин В.В., Сомонова О.В., Пантелеев М.А. и др. Диа- гностика, лечение и профилактика тромбоэмболических осложнений у онкологических и онкогематологических боль- ных. Учебное пособие. М.: ФГБОУ ДПО РМАНПО Минздрава Рос- сии, 2017. 94 с. Режим доступа: http://irbis.rmapo.ru/Uploads- FilesForIrbis/a83fd1b32862e1b191345b1aed893a4e.pdf.

  9. Шакарьянц Г.А., Буданова Д.А., Лобастов К.В. и др. Лече- ние и вторичная профилактика венозных тромбоэмболиче- ских осложнений у онкологических больных. Кардиология. 2020;60(3):71–9. DOI: 10.18087/cardio.2020.3.n904.

  10. Streiff M.B., Holmstrom B., Angelini D. et al. NCCN Guidelines Insights: cancer-associated venous thromboembolic disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–303. DOI: 10.6004/jnccn.2018.0084.

  11. Khorana A.A., Noble S., Lee A.Y.Y. et al. Role of direct oral anti-coagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Hae- most. 2018;16(9):1891–4. DOI: 10.1111/jth.14219.

  12. Young A.M., Marshall A., Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23. DOI: 10.1200/JCO.2018.78.8034.

  13. Zabolotskikh I.B., Kirov M. Yu., Afonchikov V.S. et al. Perioperative management of patients receiving long-term antithrombotic therapy. Russian Federation of anesthesiologists and reanimatologists guidelines. Vestnik intensivnoj terapii imeni A.I. Saltanova. 2021;(3):7–26. (In Russ.). DOI: 10.21320/1818–474X-2021–3–7–26.

  14. Farge D., Bounameaux H., Brenner B. et al. International clinical practice guidelines including guidance for directoral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452-e466. DOI: 10.1016/S1470–2045(16)30369–2.